Selumetinib's approval now includes children as young as 1 year old with NF1 and symptomatic, inoperable plexiform neurofibromas. The drug targets the RAS/MEK/ERK pathway, providing a non-surgical ...

Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...

Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder arising from mutations in the NF1 gene that encodes the tumour suppressor protein neurofibromin. Research has increasingly refined our ...

An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. On November 4, 2025, Pasithea Therapeutics Corp announced the ...

Panelists discuss how neurofibromatosis type 1 (NF1) is typically diagnosed in early childhood using National Institutes of Health (NIH) clinical criteria, with genetic testing supporting unclear ...

The start of human dosing in a clinical trial Monday, plus a drug approval earlier this month, together offer the potential to reshape the treatment of the rare disease neurofibromatosis type 1 (NF1).

MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral challenges associated with neurofibromatosis type 1, or NF1, a genetic ...

The research conducted by Professor Zou Zui and his team focuses on the immunoregulatory mechanisms in sepsis. As a ...